Manuscripts:

  1. Lahuerta JJ, Paiva B, et al. Depth of response in multiple myeloma: a pooled analysis of 609 patients enrolled in three PETHEMA/GEM clinical trials. To be published. 2017.
  2. Mishima Y, Paiva B, Ghobrial I, et al. The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma. Cell Rep. 2017 Apr 4;19(1):218-224.
    http://www.cell.com/cell-reports/pdf/S2211-1247(17)30357-1.pdf
  3. Halvarsson B-M, Wihlborg A-K, et al. Direct evidence for a polygenic etiology in familial multiple myeloma. Blood Advances. 2017 1:619-623
    http://www.bloodadvances.org/content/1/10/619
  4. Flores-Montero J, Paiva B, Orfao, A, et al. Next generation flow (NGF) for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia advance online publication 10 March 2017; doi: 10.1038/leu.2017.29
    http://www.nature.com/leu/journal/vaop/ncurrent/full/leu201729a.html
  5. Paiva B, et al. Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients. Blood. 2016;127(25):3165-3174.
    http://www.bloodjournal.org/content/127/25/3165
  6. Paiva B, et al. Phenotypic, transcriptomic, and genomic features of clonal plasma cells in light-chain amyloidosis. Blood. 2016;127(24):3035-3039.
    http://www.bloodjournal.org/content/bloodjournal/127/24/3035.full.pdf
  7. Paiva B, et al. Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance. Blood. 2016;127(15):1896-1906.
    http://www.bloodjournal.org/content/127/15/1896
  8. Flores-Montero J, de Tute R, Paiva B, Perez JJ, Bottcher S, Wind H, Sanoja L, Puig N, Lecrevisse Q, Vidriales MB, van Dongen JJM and Orfao A. Immunophenotype of Normal vs. Myeloma Plasma Cells: Toward Antibody Panel Specifications for MRD Detection in Multiple Myeloma. Cytometry Part B 2016; 90B: 61–72.
    http://onlinelibrary.wiley.com/doi/10.1002/cyto.b.21265/epdf
  9. Pojero F, Flores-Montero J, Sanoja L, Perez JJ, Puig N, Paiva B, Bottcher S, van Dongen JM, and Orfao A on behalf of the Euroflow group. Utility of CD54, CD229, CD319 for the Identification of Plasma Cells in Patients with Clonal Plasma Cell Diseases. Cytometry Part B (Clinical Cytometry) 201690B:91–100.
    http://onlinelibrary.wiley.com/doi/10.1002/cyto.b.21269/epdf
  10. Misiewicz-Krzeminska I, et al. Quantification of Cyclin D1, Cyclin D2, Ikaros, Aiolos, and Cerebelon Proteins by Capilary Immunoassay in Patients with Newly Diagnosed Multiple Myeloma and Analysis of their Impact on Patient Survival. EHA21 Abstract Book (2016).
    http://learningcenter.ehaweb.org/eha/2016/21st/133252/irena.misiewicz-krzeminska.quantification.of.cyclin.d1.cyclin.d2.ikaros.aiolos.html?f=p6m3e968o12153
  11. Paiva B, van Dongen JM, and Orfao A. New criteria for response assessment: role of minimal residual disease in multiple myeloma. Blood 2015; 125: 3059-3068
    http://www.bloodjournal.org/content/bloodjournal/125/20/3059.full.pdf
  12. Paiva B, Chandia M, Puig N, Vidriales MD, Perez JJ, Lopez-Corral L, Ocio EM, Garcia-Sanz R, Gutierrez NC, Jimenez-Ubieto A, Lahuerta JJ, Mateos MV, and San Miguel JF. The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma. Haematologica Feb 2015, 100 (2) e53-e55.
    http://www.haematologica.org/content/100/2/e53.full.pdf
  13. Spencer A, Mithraprabhu S, Ramachandran M, Klarica D, Hocking J, Mai L, Walsh S, Broemeling D, Marziali A, Kalff A, Wiggin M, Durie BGM, and Khong TT. Evaluation of Circulating Tumour DNA for the Mutational Characterisation of Multiple Myeloma. Blood 2015 126:368.
    http://www.bloodjournal.org/content/126/23/368
  14. Matarraz S, Paiva B, Díez-Campelo M, Bárrena S, Jara-Acevedo M, Gutiérrez ML, Sayagués JM, Sánchez ML, Bárcena P, Garrastazul MP, Berruezo MJ, Duran JM, Cerveró C, García-Erce JA, Florensa L, Méndez GD, Gutierrez O, Del Cañizo MC, van Dongen JJ, San Miguel JF, Orfao A. Immunophenotypic alterations of bone marrow myeloid cell compartments in multiple myeloma patientspredict for myelodysplasia-associated cytogenetic alterations. Leukemia. 2014 Aug;28(8):1747-50.
    http://www.nature.com/leu/journal/v28/n8/full/leu2014103a.html
  15. Kubiczkova-Besse L, Drandi D, Sedlarikova L, Oliva S,  Gambella M, Omedè P, Adam Z, Pour L, Sevcikova S, Boccadoro M, Palumbo A, Hajek R. Cell-Free DNA for Minimal Residual Disease Monitoring in Multiple Myeloma Patients. Blood 2014 124:3423
    http://www.bloodjournal.org/content/124/21/3423
  16. Matarraz S, et al. Myelodysplasia-associated immunophenotypic alterations of bone marrow cells in myeloma: are they present at diagnosis or are they induced by lenalidomide? Haematologica October 2012 97: 1608-1611
    http://www.haematologica.org/content/97/10/1608

Abstracts:

  1. Hillengass, J et al. Findings of Whole Body Computed Tomography Compared to Conventional Skeletal Survey in Patients with Monoclonal Plasma Cell Disorders – a Study of the International Myeloma Working Group. Blood 2016 128:4468.
    http://www.bloodjournal.org/content/128/22/4468
  2. Lenka Kubiczkova-Besse. Dynamics of microRNA and cellfree DNA profiles during multiple myeloma progression. Blood 2014 124:3423. http://www.bloodjournal.org/content/124/21/3423